Clopidogrel pharmacogenetics and its clinical implications.
作者： Mukesh Singh , Bipin Thapa , Rohit Arora
DOI: 10.1097/MJT.0B013E3181AFBF62
关键词: Pharmacology 、 Clopidogrel 、 CYP2C19 、 Platelet 、 Receptor 、 Medicine 、 CYP3A4 、 P2Y12 、 Pharmacogenetics 、 Antithrombotic
摘要: Pharmacogenetics encompasses a range of phenomena ranging from pharmacology to therapeutics toxicology and generally focuses on the study genetic factors related interindividual variability in drug response. Individual differences rate platelet reactivity markedly influence normal hemostasis pathologic outcome thrombosis. Response clopidogrel varies widely, with nonresponse rates various studies 4%-30% at 24 hours. Polymorphism involved response antithrombotic drugs has been described components hemostatic thrombotic systems, these include variations. Polymorphisms hepatic enzymes metabolism (e.g., CYP 1A2, CYP3A4, CYP2C19) or within membrane receptor (P2Y12) and/or polymorphism integrin alphaIIbbeta3 alpha2beta1 may affect responses could administration. In this review, we discuss pharmacogenetics phenomenon its clinical implications.
sci-hub.se 参考文章(65)
Michael Rolf Mueller, Andreas Salat, Petra Stangl, Marco Murabito, Sad Pulaki, Dagmar Boehm, Renate Koppensteiner, Erdem Ergun, Martina Mittlboeck, Wolfgang Schreiner, Udo Losert, Ernst Wolner, Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thrombosis and Haemostasis. ,vol. 78, pp. 1003- 1007 ,(1997) , 10.1055/S-0038-1657677
Paul A. Gurbel, Kevin P. Bliden, Waiel Samara, Jason A. Yoho, Kevin Hayes, Mulugeta Z. Fissha, Udaya S. Tantry, Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. Journal of the American College of Cardiology. ,vol. 46, pp. 1827- 1832 ,(2005) , 10.1016/J.JACC.2005.07.056
Luca Pontiggia, Jürg H. Beer, Stefanie Pederiva, Genetics of platelet receptor single-nucleotide polymorphisms: clinical implications in thrombosis. Annals of Medicine. ,vol. 32, pp. 10- 14 ,(2000)
Augusto Di Castelnuovo, Giovanni de Gaetano, Maria Benedetta Donati, Licia Iacoviello, Platelet glycoprotein IIb/IIIa polymorphism and coronary artery disease: implications for clinical practice. American Journal of Pharmacogenomics. ,vol. 5, pp. 93- 99 ,(2005) , 10.2165/00129785-200505020-00002
S. S. Ahmad, F. S. London, P. N. Walsh, The assembly of the factor X-activating complex on activated human platelets Journal of Thrombosis and Haemostasis. ,vol. 1, pp. 48- 59 ,(2003) , 10.1046/J.1538-7836.2003.00020.X
Paul Bray, Integrin polymorphisms as risk factors for thrombosis. Thrombosis and Haemostasis. ,vol. 82, pp. 337- 344 ,(1999) , 10.1055/S-0037-1615851
Glen E. Cooke, Yiwen Liu-Stratton, Amy K. Ferketich, Melvin L. Moeschberger, David J. Frid, Raymond D. Magorien, Paul F. Bray, Philip F. Binkley, Pascal J. Goldschmidt-Clermont, Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. Journal of the American College of Cardiology. ,vol. 47, pp. 541- 546 ,(2006) , 10.1016/J.JACC.2005.09.034
Jessica L. Mega, Sandra L. Close, Stephen D. Wiviott, Lei Shen, Richard D. Hockett, John T. Brandt, Joseph R. Walker, Elliott M. Antman, William Macias, Eugene Braunwald, Marc S. Sabatine, Cytochrome P-450 Polymorphisms and Response to Clopidogrel The New England Journal of Medicine. ,vol. 360, pp. 354- 362 ,(2009) , 10.1056/NEJMOA0809171
S. M. G. Smith, H. M. Judge, G. Peters, M. Armstrong, A. Dupont, P. Gaussem, R. F. Storey, PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets. ,vol. 16, pp. 340- 345 ,(2005) , 10.1080/00207230500120294
Eli I. Lev, Rajnikant T. Patel, Sasidhar Guthikonda, David Lopez, Paul F. Bray, Neal S. Kleiman, Genetic polymorphisms of the platelet receptors P2Y12, P2Y1 and GP IIIa and response to aspirin and clopidogrel Thrombosis Research. ,vol. 119, pp. 355- 360 ,(2007) , 10.1016/J.THROMRES.2006.02.006